Editorial comment on: Mechanisms of prostate atrophy after glandular botulinum neurotoxin type A injection: an experimental study in the rat.

摘要

Botulinum Neurotoxin Type A (BoNT-A) has recently been proposed as a novel, effective drug in the management of lower urinary tract symptoms caused by benign prostatic enlargement or other urological conditions (ie, neurogenic detrusor overactivity, detrusor-sphincter dyssynergia, motor and sensory urge, or chronic prostatic pain) [1].